Navigation Links
Codexis Names Peter Strumph SVP, Commercial Operations

REDWOOD CITY, Calif., June 28 /PRNewswire-FirstCall/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that Peter Strumph has joined the company as Senior Vice President, Commercial Operations, a new position.  Mr. Strumph will be responsible for Codexis pharmaceutical product management and manufacturing operations worldwide.  He will report to Joseph Sarret, M.D., Chief Business Officer and President, Pharmaceutical Services and Enzyme Products.  

Mr. Strumph joins Codexis with twenty years experience in senior manufacturing and operations management in the biopharmaceutical industry. He was Chief Executive Officer of Nile Therapeutics, a cardiovascular company, from 2007-2009.  Previously, he held operations leadership positions for ten years at CV Therapeutics, most recently serving as Senior Vice President, Operations.  At CVT, he oversaw all CMC (chemistry, manufacturing and controls), quality and operations functions. He also held senior operations and manufacturing management roles at Biogen, and staff and manufacturing roles at Bio-Rad Laboratories and Bayer Pharmaceuticals.  Mr. Strumph holds a Bachelor's degree in Systems Science and Engineering and an MBA from the University of Pennsylvania.  

"We are very pleased to welcome Peter Strumph to our management team," Dr. Sarret said.  "He brings Codexis extensive manufacturing management experience, with a focus on commercializing pharmaceuticals products. His breadth of experience in managing successful global pharmaceuticals operations will enable us to better serve our expanding customer base."

Codexis, Inc. is a leading provider of optimized biocatalysts that make existing industrial processes faster, cleaner and more efficient than current methods and have the potential to make new industrial processes possible at commercial scale.  Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. The company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals. 

Contact: Media; Lyn Christenson,, 650-421-8144 or Saskia Sidenfaden,, 212-827-3771.  Investors; Derick Sutton,, 650-421-8130

SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis CEO Alan Shaw Named Ernst & Young Entrepreneur Of The Year® 2010 Recipient in Northern California
2. Codexis, Inc. Announces Pricing of Initial Public Offering
3. Codexis Expands Pharmaceutical Manufacturing Partnerships
4. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Codexis Expands Collaboration with Teva
6. Codexis Names Fernando Valle Research Fellow
7. Gentris Corporation Names New Chief Executive Officer
8. Medical Device and Diagnostic Industry Names Envoy Medical a Company to Watch
9. Apnex Medical, Inc. Names Chas McKhann President, Chief Executive Officer
10. Aveta Inc. Names Josh Valdez President of MSO of Puerto Rico, Inc.
11. Kincannon & Reed Names David G. Jensen as Managing Director, Biopharma Life Sciences
Post Your Comments:
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
Breaking Medicine News(10 mins):